Stuart Campbell

Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk

Aruna D. Pradhan, Robert J. Glynn, Jean‐Charles Fruchart et al. · New England Journal of Medicine · 2022 · 638 citations · Full text

Pitavastatin versus pravastatin in adults with HIV-1 infection and dyslipidaemia (INTREPID): 12 week and 52 week results of a phase 4, multicentre, randomised, double-blind, superiority trial

Judith A. Aberg, Craig A. Sponseller, Douglas Ward et al. · The Lancet HIV · 2017 · 83 citations

Superiority Trial, Cardiovascular Disease, Treatment And Prevention +9

Effects of Steady-State Lopinavir/Ritonavir on the Pharmacokinetics of Pitavastatin in Healthy Adult Volunteers

Roger Morgan, Stuart Campbell, Kazuhito Suehira et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2012 · 31 citations

Comparison of the Lipid-Lowering Effects of Pitavastatin 4 mg Versus Pravastatin 40 mg in Adults With Primary Hyperlipidemia or Mixed (Combined) Dyslipidemia: A Phase IV, Prospective, US, Multicenter, Randomized, Double-blind, Superiority Trial

Craig A. Sponseller, Roger Morgan, Vladimir A. Kryzhanovski et al. · Clinical Therapeutics · 2014 · 28 citations

Metabolic Syndrome, Lipid-lowering Effects, Superiority Trial +8

Comparison of the Safety, Tolerability, and Pharmacokinetic Profile of a Single Oral Dose of Pitavastatin 4 mg in Adult Subjects With Severe Renal Impairment Not on Hemodialysis Versus Healthy Adult Subjects

Roger Morgan, Stuart Campbell, Christine Yu et al. · Journal of Cardiovascular Pharmacology · 2012 · 26 citations

Renal Pathology, Dialysis Therapy, Hyperlipidemia +18